ClinicalTrials.gov record
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older Adults

ClinicalTrials.gov ID: NCT02723773

Public ClinicalTrials.gov record NCT02723773. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 7:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Efficacy, Safety and Immunogenicity of GSK Biologicals' HZ/su Vaccine GSK1437173A in a Phase IIIb, Open-label, Long-term Follow-up Study (ZOE-LTFU) of Studies 110390/113077 (ZOSTER-006/022) and Assessment of Additional Doses in Older Adults

Study identification

NCT ID
NCT02723773
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
7,539 participants

Conditions and interventions

Interventions

  • Herpes Zoster Vaccine GSK1437173A Biological

Biological

Eligibility (public fields only)

Age range
50 Years and older
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 15, 2016
Primary completion
Jun 27, 2023
Completion
Jan 29, 2024
Last update posted
Dec 11, 2025

2016 – 2024

United States locations

U.S. sites
25
U.S. states
13
U.S. cities
21
Facility City State ZIP Site status
GSK Investigational Site Phoenix Arizona 29651
GSK Investigational Site Phoenix Arizona 84123
GSK Investigational Site Phoenix Arizona 85018
GSK Investigational Site Phoenix Arizona 85020
GSK Investigational Site Phoenix Arizona 85306
GSK Investigational Site Spring Valley California 91978
GSK Investigational Site Hallandale Florida 85213
GSK Investigational Site Boise Idaho 83712
GSK Investigational Site Wichita Kansas 67207
GSK Investigational Site Columbia Maryland 21045
GSK Investigational Site Elkridge Maryland 21075
GSK Investigational Site Cary North Carolina 27518
GSK Investigational Site Charlotte North Carolina 28209
GSK Investigational Site Hickory North Carolina 28601
GSK Investigational Site Salisbury North Carolina 28144
GSK Investigational Site Wilmington North Carolina 28412
GSK Investigational Site Winston-Salem North Carolina 27103
GSK Investigational Site Cleveland Ohio 44122
GSK Investigational Site Wadsworth Ohio 44281
GSK Investigational Site Pittsburgh Pennsylvania 15236
GSK Investigational Site Uniontown Pennsylvania 15401
GSK Investigational Site Mt. Pleasant South Carolina 29464
GSK Investigational Site Bristol Tennessee 37620
GSK Investigational Site San Antonio Texas 78229
GSK Investigational Site Newport News Virginia 23606

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 136 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02723773, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 11, 2025 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02723773 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →